Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD 452 in Adults With Active RA on Methotrexate
NCT00141934Phase 2Completed
- Sponsor
- Nxera Pharma
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mefloquine in rheumatoid arthritis (RA) (4 arms), sponsored by Nxera Pharma. Primary endpoint: American College of Rheumatology 20% response at 12 weeks. Started Aug 2005; status: completed.
02
Drugs
mefloquine
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00141934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00141934.